A Randomized, Double Blind, Parallel Group, Placebo-controlled Trial to Study the Efficacy and Safety of Two Oral Doses of Prurisol Administered Twice Daily for Twelve Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 15 Aug 2017
At a glance
- Drugs Abacavir (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Innovation Pharmaceuticals
- 15 Aug 2017 According to an Innovation Pharmaceuticals media release, this trial is anticipated to be completed in fourth quarter 2017.
- 18 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 18 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.